MA27474A1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA27474A1
MA27474A1 MA28223A MA28223A MA27474A1 MA 27474 A1 MA27474 A1 MA 27474A1 MA 28223 A MA28223 A MA 28223A MA 28223 A MA28223 A MA 28223A MA 27474 A1 MA27474 A1 MA 27474A1
Authority
MA
Morocco
Prior art keywords
relates
molecules
techniques
vectors
vaccine
Prior art date
Application number
MA28223A
Other languages
English (en)
Inventor
Gerald Wayne Gough
Christopher Michael Roberts
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27474A1 publication Critical patent/MA27474A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des techniques et des compositions qui conviennent pour le traitement et la prévention des infections par le papillomavirus humain. Cette invention concerne, en particulier, des molécules d'acides nucléiques codantes pour El et/ou E2 et des vecteurs adaptés pour l'apport de vaccin à ADN et, des compositions pharmaceutiques contenant ces molécules. Cette invention concerne aussi des techniques de fabrication de ces molécules, de ces vecteurs et de cette composition.
MA28223A 2002-10-03 2005-04-15 Vaccin MA27474A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222953.2A GB0222953D0 (en) 2002-10-03 2002-10-03 Novel Compounds

Publications (1)

Publication Number Publication Date
MA27474A1 true MA27474A1 (fr) 2005-08-01

Family

ID=9945247

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28223A MA27474A1 (fr) 2002-10-03 2005-04-15 Vaccin

Country Status (21)

Country Link
US (2) US20060165713A1 (fr)
EP (1) EP1546191A2 (fr)
JP (1) JP2006516386A (fr)
KR (1) KR20050050115A (fr)
CN (1) CN100393878C (fr)
AR (1) AR041515A1 (fr)
AU (1) AU2003294672A1 (fr)
BR (1) BR0314986A (fr)
CA (1) CA2500093A1 (fr)
CO (1) CO5580837A2 (fr)
GB (1) GB0222953D0 (fr)
IS (1) IS7775A (fr)
MA (1) MA27474A1 (fr)
MX (1) MXPA05003558A (fr)
NO (1) NO20051561L (fr)
NZ (1) NZ539154A (fr)
PL (1) PL376534A1 (fr)
RU (1) RU2354701C2 (fr)
TW (1) TW200411055A (fr)
WO (1) WO2004031222A2 (fr)
ZA (1) ZA200503201B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE544466T1 (de) 2002-10-29 2012-02-15 Coley Pharm Group Inc Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
PE20081723A1 (es) * 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
CA2803058C (fr) 2010-06-25 2022-07-05 Vaccibody As Structures proteiniques homodimeres
JP6663438B2 (ja) * 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
CA3023022A1 (fr) * 2016-05-04 2017-11-09 Transgene Sa Polytherapie avec un ligand de tlr9 cpg

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
BR0112637A (pt) * 2000-07-21 2003-06-10 Glaxo Group Ltd Sequências do vìrus do papiloma códon-otimizadas

Also Published As

Publication number Publication date
RU2354701C2 (ru) 2009-05-10
CO5580837A2 (es) 2005-11-30
NZ539154A (en) 2007-05-31
RU2005109155A (ru) 2006-03-10
EP1546191A2 (fr) 2005-06-29
TW200411055A (en) 2004-07-01
MXPA05003558A (es) 2005-06-03
GB0222953D0 (en) 2002-11-13
NO20051561D0 (no) 2005-03-23
PL376534A1 (pl) 2006-01-09
BR0314986A (pt) 2005-08-09
WO2004031222A3 (fr) 2004-08-19
JP2006516386A (ja) 2006-07-06
AR041515A1 (es) 2005-05-18
CA2500093A1 (fr) 2004-04-15
CN1720261A (zh) 2006-01-11
IS7775A (is) 2005-03-29
ZA200503201B (en) 2006-06-28
WO2004031222A2 (fr) 2004-04-15
US20060165713A1 (en) 2006-07-27
NO20051561L (no) 2005-06-02
US20070264283A1 (en) 2007-11-15
CN100393878C (zh) 2008-06-11
AU2003294672A1 (en) 2004-04-23
KR20050050115A (ko) 2005-05-27

Similar Documents

Publication Publication Date Title
MA27699A1 (fr) Vaccin contre vhc
MA27474A1 (fr) Vaccin
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE602004026053D1 (fr)
EP1362127A4 (fr) Medicaments a base de serpine pour le traitement de l'infection par vih et utilisation de ceux-ci
EP1673078A4 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
NO20025450D0 (no) Ny farmasöytisk sammensetning
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ATE355288T1 (de) Verbindungen und therapeutische methoden
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
WO2005091937A3 (fr) Compositions utilisees dans le traitement d'infections microbiennes
ATE213233T1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
FR2868318B1 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih
DK0811068T3 (da) Humane DNase I varianter
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation